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Tratamento da mucosite em pacientes submetidos a transplante de medula óssea: uma revisão
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ABSTRACT
Objective: To identify therapeutic measures to reduce the severity of  oral mucositis in adult patients undergoing bone marrow transplantation
(BMT). Methods: A systematic review using the following databases: LILACS, MEDLINE, CINAHL, EMBASE, CENTRAL (Cochrane
Central) and DARE (Database of  abstracts of  reviews of  effects), for the period between 1972 to July 2010, using the key words mucositis,
stomatitis and bone marrow transplantation. Results: We identified 3,839 abstracts, 22 of  which were included in the systematic review; these
articles identified 14 topical and systemic interventions, among which eight showed statistical significance for the reduction of this complication.
The topical therapies were: cryotherapy, chlorhexidine, glutamine, laser and Traumeel ®. The systemic therapies were: amifostine, Granulokine
®, and palifermin. Conclusion: The heterogeneity of the results of these interventions and the lack of better elucidation for healthcare
practice indicate the need for more accurate research to identify the effectiveness of topical therapies for repair of mucosal cells.
Keywords: Mucositis/therapy; Stomatitis; Bone marrow grafted; Nursing care
RESUMO
Objetivo: Identificar as medidas terapêuticas para redução da gravidade da mucosite oral em pacientes adultos submetidos ao Transplante
de Medula Óssea (TMO). Métodos: Revisão sistemática nas bases de dados: LILACS, MEDLINE, CINAHL, EMBASE; CENTRAL
(Cochrane Central) e DARE (Database of  abstracts of  reviews of  effects), no período de 1972 a julho de 2010, utilizando os descritores mucositis,
stomatitis e bone-marrow-transplantation. Resultados: Identificaram-se 3.839 resumos, dos quais 22 foram incluídos na revisão sistemática que
descreveram 14 intervenções tópicas e sistêmicas, dentre as quais oito com significância estatística para a redução dessa complicação. As
terapias tópicas foram a crioterapia, clorexidine, glutamina, laser e Traumeel® e as sistêmicas, amifostine, Granulokine® e palifermin.
Conclusão: A heterogeneidade dos resultados dessas intervenções e a falta de melhor elucidação para a prática assistencial indicam a
necessidade de pesquisas mais precisas para identificar a efetividade de terapias tópicas para a reparação celular das mucosas.
Descritores: Mucosite/terapia; Estomatite; Transplante de medula óssea; Cuidados de enfermagem
RESUMEN
Objetivo: Identificar las medidas terapéuticas para la reducción de la gravedad de la mucositis oral en pacientes adultos sometidos a
Transplante de Médula Ósea (TMO). Métodos: Se trata de una revisión sistemática en las bases de datos: LILACS, MEDLINE, CINAHL,
EMBASE; CENTRAL (Cochrane Central) y DARE (Database of  abstracts of  reviews of  effects), en el período de 1972 a julio del 2010,
utilizando los descriptores mucositis, stomatitis y bone-marrow-transplantation. Resultados: Se identificaron 3.839 resúmenes, y de éstos 22
fueron incluídos en la revisión sistemática que describieron 14 intervenciones tópicas y sistémicas, de las cuales ocho con significancia
estadística para la reducción de esa complicación. Las terapias tópicas fueron la crioterapia, clorexidine, glutamina, laser y Traumeel® y las
sistémicas, amifostine, Granulokine® y palifermin. Conclusión: La heterogeneidad de los resultados de esas intervenciones y la falta de
mayor claridad para la práctica asistencial indican la necesidad de investigaciones más precisas para identificar la efectividad de terapias
tópicas tendientes a la reparación celular de las mucosas.
Descriptores: Mucositis/terapía ; Estomatitis; Trasplante de médula óssea; Cuidado de enfermería
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INTRODUCTION
The Bone Marrow Transplant (BMT) is a therapeutic
option for oncohematological diseases, which is
considered effective increasing patients’ survival rates.
According to the Associação Brasileira de
Transplantes de Órgãos (Brazilian Association for Organ
Transplants), 1.129 transplants occurred in Brazil between
January and September 2010, 648 of which were
autologous and 481, allogeneic(1).
However, it is important considering the side effects
caused by BMT, among which are: bone marrow aplasia,
nausea, vomiting, diahrrea, Graft-Versus-Host Disease,
and mucositis. Mucositis affects approximately 75% of
the patients who undergo ablative chemotherapy sessions,
or total body irradiation, as preparation means to the
transplant, which directly impact on patients’ general state
and are significantly associated with an increase in general
mortality(2).
Oral mucositis is an inflammation of the mucosa
that is characterized by colour alteration, atrophy,
ulceration, edema, and alteration of the local perfusion.
Early signals that indicate the mucosa is compromised
are visible during the chemotherapy / radiation therapy
sessions. In the first two weeks after the transplant, these
signals will worsen(3).
Despite the morbidity and the impacts brought by
oral mucositis to patients’ quality of life during the
treatment and control of oncohematological diseases,
there is no effective evidence of prophylactic agents, or
agents for its treatment(4). The lack of evidence limits
the ability to measure benefits, risks, and costs associated
to the prevention, diagnosis and treatment of mucositis
and its complications. Therefore, to identify intervention
actions that can be taken to minimize the seriousness of
mucositis is the objective of the present investigation.
Considering the above said, this study aimed to
answer the questions described below:
- What are the recommended actions to prevent and
treat oral mucositis in adult patients who have undergone
BMT?
- How effective are the interventions identified in
reducing the seriousness of oral mucositis in adult
patients who underwent a BMT?
METHODS
The present study is a systematic literature review
(SLR), performed through a retrospective analysis of
primary studies that focused on the oral mucositis
treatment. The methodological procedures were based
on Cochrane Collaboration (5) recommendations,
characterized by a thorough analysis of the selected
studies, according to their evidences and relevance in
the area; data synthesis and interpretation.  The search
strategy used to identify the articles was based on an
initial selection of articles from Literatura Latino-
Americana and of Caribe em Ciências da Saúde
(LILACS), Medical Literature Analysis and Retrieval
System on-line (MEDLINE), Cumulative Index to
Nursing and Allied Health Literature (CINAHL),
EMBASE; CENTRAL (Cochrane Central register of
controlled trials), and DARE (Database of  abstracts of  reviews
of  effects), all available at Cochrane Library. At this stage,
besides primary studies, narrative reviews and clinical
guidelines were also selected in order to synthetize the
literature related to such theme. Inverse search was also
utilized: this method consists of selecting primary
documents recovered from the previous search. After
the first study identification phase was concluded, studies
were selected for a quality assessment.
The descriptors used were: Mucositis, Mucositis AND
Bone Marrow Transplantation, Stomatitis AND Bone Marrow
Transplantation. The search began in 2004 and had updates
until July 2010, covering the period from 1972 to 2010,
with no language restrictions.
The inclusion criteria for the selected articles were:
randomized controlled clinical trials (RCT), double-blind
and mono-blind studies, studies with no blinding method
that tested treatments so as to verify their efficacy and
safety preventing and controlling serious oral mucositis.
The study population was comprised of adult patients
who had undergone BMT, aged 18 or more.
The exclusion criteria were: studies that, further than
approaching mucositis and stomatitis assessment,
prevention, and treatment, included the candidiasis
treatment in patients who had gone through
chemotherapy and/or radiation therapy sessions that
were not related to BMT, and studies whose population
was comprised exclusively of  children and adolescents.
In order to enable the analysis in the present SLR, only
RCTs were included.
Analysis Method
The studies analysis was performed by three experts
in the area that independently verified the agreement
regarding the pre-selection of articles, and in case of
disagreement, read the article integrally for the final
selection. The pre-selected primary articles were
submitted to analysis, based on Hadorn et al.(6) criteria,
with regard to the quality of  the controlled studies. Those
which presented methodological problems were
excluded. In order to extract data from the articles
included in the SLR, an instrument with the following
items was used: publication date, authors, title of the
study, country of  publication, type of  publication
(journal, book, dissertation, thesis, etc), type of  study,
objective, context (experimental, hospital-related,
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ambulatory-related), population/sample (experimental
and controlled), randomization method description,
blinding, population characteristics (age bracket, gender,
race, education, diseases, and type of conditioning),
caregiver’s professional category, patients’ inclusion
criteria, intervention performed – both for the
controlled and experimental groups – results assessment
and measurement, statistical tests used, scales utilized to
assess the intervention, research findings, and evidence
level.
RESULTS
Three thousand eight hundred and thirty nine
summaries were identified with the uniterm mucositis. Two
thousand eight hundred and twenty seven of which were
excluded due to the fact they did not analyse the mucositis
treatment in patients who had undergone a BMT. From
the 1,012 summaries with Mucositis AND Bone Marrow
Transplantation, Stomatitis AND Bone Mar row
Transplantation, 188 were selected, for they were
Randomized Controlled Trials (RCT). After the articles
were read, 166 were excluded because they included
children in their population, or because their main aim
was not to reduce serious mucositis. Therefore, 22 RCTs
were selected for being related to the theme “mucositis
treatment in adult patients who underwent a BMT”.
The synthesis of the 22 studies identified with regard
to their authors, country of origin, study population,
treatment type and time, results obtained, and scale
utilization to assess the results can be observed through
Table 1 data.
Amifostine is a selective antioxidant cytoprotective
agent with a wide action range. When compared to the
group who had not received any previous treatment,
this drug demonstrated a protective effect, reducing the
oral mucositis average degree (Degree 1 versus 2 p= 0,01)
and the frequency of serious mucositis (WHO degrees
3 or 4; respectively, 12% vs 33% p= 0,02)(7).
Caphosol® (calcium phosphate) is an artificial saliva
solution, indicated to lubricate the mucosa.  When
compared to the control group, it did not present a
significant statistical difference diminishing the seriousness
of mucositis(8).
By using ice, cryotherapy, has been widely used for
the oral mucositis treatment in oncology patients.  The
present review identified a study with 80 patients that
analysed the topical use of cryotherapy compared to
the use of a physiological solution in room temperature.
Results showed its protective and therapeutic effect,
diminishing the seriousness of mucositis (Degree 3-4)
from 14% to 74%, p=0,0005(9).
Chlorhexidine digluconate is an important antiseptic
that can be used on the skin and mucosae due to its low
toxicity. It is also used for mouth rinsing due to its
antimicrobial action. This type of therapy presented a
protective effect when compared to the placebo(10-11).
Glutamine (l-glutamine or L- alanyl-L- glutamine) is
used in high doses by rapid division cells, including
leukocytes, to provide energy and favour the biosynthetic
process of nucleotides 11. No relevant statistical
difference was observed reducing oral mucositis(12-14).
Granulokine® (Filgrastim G-CSF), a human
granulocyte colony stimulating factor whose action over
the bone marrow increases the production and mobilization
of neutrophils, did not present a significant statistical
difference reducing the mucositis seriousness(15-18).
A study which compared the intensive oral hygiene
regime (IOH) with limited oral hygiene (LOH) did not
present significant statistical difference(19). It is relevant
highlighting that the IOH included a complete exam of
the mouth, in order to detect and treat cavities,
periodontal lesions, periapical disease, mispositioned
teeth, and assess dental prostheses adequacy, while the
LOH excluded the preventive treatment, as well as teeth
and gums brushing. Both groups rinsed their mouths
with chlorhexidine.
Histamine presents a topical application, as a gel that
reduces tissue damage, diminishing the generation of
reactive oxygen species through the connection with H2
receptors, and the production of proinflammatory
cytokines stimulating the phagocytes. The analysis
performed did not show any significant difference
reducing the mucositis severity(20).
Misoprostol (Prostaglandin E1 - Cytotec®) is a drug
that reduces the ulceration risk, induced by nonsteroidal
anti-inflammatory drugs(21). With regard to the use of
Misoprostol, a synthetic analog of prostaglandin E1,
one of the studies compared it to a placebo; both were
presented in a tablet format to patients who had gone
through Cyclophosphamide and Total Body Irradiation
(TBI) conditioning(21). Another study used Misoprostol
in tablets, comparing it to a placebo group,
concomitantly with etoposide, carboplatin,
iphosphamide and conditioning regimens(22). The present
review verified after analysing both studies that no
significant statistical difference was found(21-22).
The Helium –Neon Laser (He- Ne) 60mW is a
current topical therapy that was assessed by a study that
compared its action in parts of the mucosa in relation
to the contralateral area, where a reduction on the
mucositis seriousness was observed, on the 6th and 9th
days after the transplant(23). Another study also verified
this therapy beneficial effects, however, the methodology
did not adopt a control group comparison(24).
Palifermin is a human recombinant keratinocyte
growth factor, a trial(25) revealed it reduces the incidence
of  degrees III and IV, while also reducing the febrile
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Table 1 – Synthesis of  the selected studies on mucositis treatment in patients who have undergone Bone Marrow
Transplant. 
Therapy Author Method Patients (n) Interventios Variables Results 
Assessment 
Scale 
Amifostine 
Spencer A, 
Horvath N, 
Gibson J, 
Pr ince HM, 
Herrmann R, 
Bashford J, 
et al.(7) 
RCT, Multi-
centric, 
Hospital-
based.  
Follow up: 
18 months 
90  
SG= 43  
CG= 47 
Amifostine 
910mg/m2 before 
the BMT 
conditioning (SG) 
vs no Amifostine 
before the BMT 
conditioning (CG) 
Mucositis 
occurrence 
and 
seriousness 
analg esic and  
NPT use  
Reduction of the oral 
mucosit is degree 
SG 1 vs CG 2 
(p=0.01) and degrees 
3  and 4 SG 12% vs 
CG 33%  (p= 0.02)  
WHO e 
EORTC 
Caphosol 
P apas AS, 
Clark RE, 
Martuscelli 
G, 
O´Loug hlin 
KT, 
Johansen E, 
Miller KB.(8) 
Double-
blind RCT 
95  
SG= 50  
CG=45 
Mouth rinse wit h 
Caphosol 
(Calcium 
Phosphate - SG) v s 
fluor ine solution 
(CG) 
Mucositis 
seriousness 
Mucosit is days 
(p=0,001) 
Duration of pain 
(p=0,0001) 
Morphine 
days( p=0,0001)  
NIDCR 
Cryotherapy 
L illeby K, 
Garcia P , 
Gooley T, 
McDonnell 
P, Taber R, 
Holmberg L, 
et al.(9) 
Double-
blind RCT 
40  
SG= 20 
CG=20 
Cryotherapy (SG) 
before  and after 
the melphalan 
perfusion, 
compared to a 
mouth r insing 
wit h saline 
solut ion (CG) in 
room temperature 
Mucositis 
seriousness, 
narcotic use, 
NPT days, 
hospital 
admission and 
weight loss  
Reduction of the 
mucosit is ser iousness 
when compared to 
the saline solution in 
room t emperature 
(p=0,0005) 
NCI grading 
system 
F errett i GA, 
Ash RC, 
Brown AT, 
Parr MD, 
Romond 
EH, Lillich 
TT.(10) 
Double-
blind RCT 
51 
SG= 24  
CG= 27 
Mouth wash with 
chlorhexidine 
(SG) VS no 
chlorhexidine 
(CG), both for 60 
days 
Mucositis 
seriousness 
and 
colonization 
by  
streptococci 
and candida 
Reduction of 
mucosit is ser iousness 
by the 7 th day: 
p<0,05 
Mucosit is resolut ion 
by the 25th day after 
the BMT: p<0,05 
Reduction of the 
colonization by 
streptococci: 
p<0,001 
Lindquist and 
Tanner modified 
index 
Chlorhexidine 
Weisdorf DJ, 
Bostrom B, 
Raether D, 
Mattingly M, 
Walker P, 
Pihlstrom B, 
et al.(11) 
Double-
blind RCT 
100 
SG= 50  
CG= 50 
Mouthwash for 
30s, three times a 
day, from D-8 to 
D+35 
Reduction of 
dental plaque 
Reduction of dent al 
plaque ( p=0,06) 
Lindquist and 
Tanner modified 
index 
Anderson 
PM, Ramsay 
NK, Shu 
XO, 
Rydholm N, 
Rog osheske 
J , Nick low R, 
et al.(12) 
Double-
blind RCT 
193 
SG= 98  
SG= 95 
Glutamine ( SG)  vs  
placebo (CG). 
Oropharyngeal 
mucosit is 
seriousness, 
oral pain, 
opioids use, 
NPT use, and 
hospital 
admission 
days.  
Reduction of oral 
mucositis in 
aut olog ous BMT  
(p=0,05) 
Not mentioned 
Blijlevens NM, 
Donnely JP, 
Naber AH, 
Schattenberg 
AV, DePauw 
BE.(13 ) 
Double-
blind RCT 
32 patient s 
with 
haematological 
cancer  (SG). 
The number 
of patients in 
the CG was 
not mentioned 
Glutamine 
supplement in t he 
NPT (SG) vs only  
NPT (CG) 
Transplant 
days, oral 
mucosa 
integrity, RCP 
concent ration  
Improvement in the 
Mucosa Integr ity , 
reduction in the 
concent ration of  
Reactive C Protein 
(RCP) D+21 af ter 
the BMT  for 
patients in the SG 
(p=0,003) 
WHO and DMS 
Glutamine 
Coghlin 
Dickson TM, 
Wong RM, 
Off rin RS, 
Shizuru JA, 
Johnston L J, 
Hu WW, et 
al.(14) 
Double-
blind RCT 
58  
SG= 29 
CG= 29 
Oral 
administration of 
Glutamine ( SG)  vs 
placebo 
administration 
(CG) 
NP T use, 
mucosit is 
seriousness , 
and diahrrea  
There was no 
significant diff erence 
reducing the 
seriousness of 
mucosit is in either 
g roup 
Stanford 
University 
Hospital BMT 
tox icity scale. 
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Therapy  Author Method Patient s (n) Interventios Variables Result s 
Assessment 
Scale  
Nemunaitis J , 
Rosenfeld 
CS, Ash R, 
Freedman 
MH, Deeg 
HJ, 
Appelbaum 
F, et al.(15)  
Double-
blind RCT 
109 
SG= 53 
CG= 53 
SG (G-CSF) IV 
administration for 
4 hours  vs 
placebo 
Perfusion from D 
0 up to D+20 
Neutrophil count, oral 
infection, hospital 
admission duration  
The absolute 
neut ropenia 
time  was 
short er for the 
SG (p=0,0001) 
Reduct ion of 
Degrees III 
and IV 
mucositis 
incidence 
(p=0,005) and 
infection 
(p=0,001) 
Not  
ment ioned 
Van der  Lelie 
H, Thomas 
BL, Van 
Oers RH, 
Ek-Post M, 
S jamsoedin 
SA, Van 
Dijk-
Overtoom 
ML, et al. (16)  
Double-
blind RCT 
36 
SG= 18  
CG= 18 
SG: 300  mg GM-
CSF in 2% 
methylcellulose gel 
CG: 
methylcellulose gel 
Both applied daily 
in the mout h 
mucosa  
Mucositis seriousness 
and pain.  
Secondary outcomes: 
need for NPT, and 
morphine, fever and 
infection incidence, 
neutropenia and 
hospital admission 
duration.  
There was no 
sig nificant  
reduction of 
the mucositis 
seriousness 
comparing 
bot h groups.  
WHO 
Valcárcel D, 
Sanz MA Jr , 
Sureda A, 
Sala M, 
Muñoz L, 
Subirá M, et 
al.( 17) 
Double-
blind RCT 
41 
SG= 18  
CG= 23 
Mouthwash with 
GM-CSF (SG) vs 
saline solution 
(CG) 
Mucositis seriousness 
There was no 
sig nificant  
dif ference 
between the 
groups 
Not  
ment ioned 
GM-CSF 
Dazzi C, 
Cariello A, 
Giovanis P, 
Monti M, 
Vert ogen B, 
Leoni M, et  
al.( 18) 
Double-
blind RCT 
36 
SG= 18  
CG= 18 
GM-CSF vs 
placebo, 
mouthwash once a 
day  
Mucositis seriousness 
There was no 
sig nificant  
reduction of 
the mucositis 
seriousness 
comparing 
bot h groups 
NCI-CTC 
Oral Hygiene 
Borowski B, 
Benhamou 
E, Pico JL, 
Laplanche A, 
Margainaud 
JP, Hayat 
M.(19)  
RCT 
150 
SG= 75 
CG= 75 
Limited oral 
hygiene compared 
to intensive oral 
hygiene  
Mucositis r isk and 
duration  
There was no 
sig nificant  
reduction of 
the ser iousness 
comparing 
bot h groups  
NCI-CTC 
Histamin 
Elad S , 
Ackerst ein A, 
B itan M, 
Shapira MY, 
Resnick I, 
Gesundheit  
B , ET al.(2 0) 
Double-
blind RCT 
44 
SG= 21 
CG= 23 
Histamine 
Mucositis duration, 
number of admission 
days 
No signif icant 
reduction of 
mucositis 
duration 
p=0.06. 
NCI and 
OMAS score 
Misoprostol 
Dueñas-
Gonzales A, 
Sobrev illa-
Calvo P, 
Fr ias-
Mendiv il M, 
Gallardo-
Rincon D, 
Lara-Medina 
F, Aguilar -
Ponce L , et 
al.( 21) 
Double-
blind RCT 
16 
SG= 9   
CG= 7  
Misoprostol v s 
placebo 
Mucositis seriousness 
and duration, diahrrea 
and number of 
admission days 
Mucositis 
seriousness 
and duration 
were 
sig nificant ly 
hig h in patients 
who were 
treated wit h 
misoprostol 
WHO 
 
L abar B , 
Mrsic M, 
Pav letic Z, 
Bog danic V, 
Nemet D, 
Aurer I, et 
al.( 22) 
Double-
blind RCT 
60   
SG= 31 
CG= 29 
Misoprostol vs 
placebo 
Mucositis seriousness 
and incidence 
There was no 
statistically 
sig nificant  
dif ference 
WHO 
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neutropenia, and infection incidence, as well as parenteral
nutrition use. It suggests a significant reduction for
Degree IV mucositis; nevertheless, insufficient data were
presented regarding the confidence interval and the
relative risk, necessary for the significance analysis.
Povidine is an antiseptic. A study compared Povidine
with a saline solution, and it did not present a significant
statistical difference, but revealed risks with regard to its
significant use(26).
Sucralphate (sucrose octasulfate, polyaluminium
hydroxide) is often utilized in the treatment of gastric
and duodenal ulcer diseases. It did not present a
significant statistical difference reducing oral mucositis,
however, it reduced diahrrea p=0,005(27).
Traumeel® is a plant extract and mineral salts
compound: Arnica Montana, Calendula officinalis, Achillea
millefolium, Matricaria chamomilla, Symphytum officinale, Atropa
belladonna, Aconitum napellus, Bellis perennis, Hypericum
perforatum, chinacea angustifólia, Echinacea purpúrea, Hamamelis
virginica, Mercurius solubis and Herba sulfuris. When compared
with a placebo, given to a group of  15 patients,
investigators observed a slight protective effect(28).
 
Ther apy  A uthor  Me thod Pa tient s (n) Int erv entios Va ria bles Re sult s 
A ssessm ent 
S ca le 
Laser 
th erap y 
Barasch A ,  
Peter so n  DE , 
T anzer  JM ,  
D ’Am bro sio  J A , 
N uk i K , 
S chu b ert M M, 
et al .( 23) 
D ou b le-
b lind  RC T  
22 au to lo go us  
BM T  patient s 
w ere in th e  
SG : tr eatmen t 
on  o ne o f th e 
sid es o f th e 
mo u th m ucosa  
CG :  
con tr alater al 
sid e of  th e 
mu co sa,  w h ich 
did  no t receive 
treatm en t   
L aser th erap y w ith  
h el iu m- neo n , d aily, 
d u ring  5  con secu tive 
d ays , b eginn in g o n 
D -2  o r D -1,  w ith  
as sessmen ts  on  days  
+ 3 , + 6,  + 9 ,+  12 , +  
1 5,  + 1 8 and  + 21.  
M u cos itis  
in ciden ce and  
ser iousn ess , 
and  pain  
in ten si ty  
20 o ut  o f 2 2 
p atients  
co mp leted th e 
s tud y.  
Red uct ion  o f th e 
m uco s itis  
s eriou sness,  b ut 
n o  in cid en ce 
r edu ctio n .  
O ral  
M u cositis 
I n dex  S cale 
( OM I-A  and  
O M I-B),  
E C OG , an d 
V isu al 
A n alogu e 
s cale (V AS ) 
t o analyse 
t he pain  
in tens i ty 
 
Co w en D , 
T ard ieu  C,  
S chu b ert M , 
Peter so n  D,  
R esb eu t M,  
Fau ch er C,  
Fr anq uin  JC.  (24)  
D ou b le-
b lind  RC T  
30 S G=  Laser 
th erap y co m  
hel ium -n eon  
(He- Ne) 
CG =  ligh t 
app l icatio n,   no  
men tio n o f the  
nu m ber  of 
pat ien ts   
S G:  Laser ther apy 
w ith  hel iu m -neon  
( He-N e) dai ly 
ap p lications  as  of  D-
5  up  un ti l D -1,  in  
f iv e diff erent  
an atomic si tes . C G:  
l igh t ap p lication .   
M u cos itis  
ser iousn ess  
and  in ciden ce, 
or al p ain , 
mo rp h in e use, 
xero s tom y and  
need  fo r NP T 
Laser  ap p lication  
r edu ced th e 
m uco s itis  
s eriou sness 
(p = 0.03 ) 
M uco si ti s 
I ndex (D MI) 
an d  
cu mu lat iv e 
o ral  
m u cos it is  
s co re 
( CO MS) 
Pal if erm in  
Sp ielb erger  R ,  
S ti ff P,  
B ens inge r W,  
G en tile T,  
W eisd or f D,  
K ew alram an i T,  
et al .( 25) 
D ou b le-
b lind ,  ph ase 
II I  R CT , 
w it h a 19 
mo n th  
d urat io n 
212   
SG =  1 06 
CG =  106  
S G:  p al i ferm in 
( 60m g/ kg o f b od y  
w eigh t/  d ay) vs  IV  
p lacebo  (CG ) 
M u cos itis  
in ciden ce and  
ser iousn ess , 
xero s tom y,  
op ioid  and  
NPT  u se  
The in ciden ce of  
D egrees  3-4  in  
th e SG  as o f 
6 3% , an d 9 8%  in  
th e CG  
(p = 0,00 1) 
W HO , 
R TO G, 
W CC NR  
Po vidin e 
Vo ku rk a S , 
B ystr ick á E,  
K oza V ,  
S cud lov á J , 
Pav lico vá V,  
Valent ov á D , et 
al .( 26) 
D ou b le-
b lind  RC T  
132 SG =  67 
C G=  65 
M o u thw ash w ith 
p o vidin e (SG ) –  
io din e 1 :1 00 v s 
p h ysio lo gical 
so lu tion  (CG ),  
p rep ared  in th e 
m o rn in g 
M u cos itis  
ser iousn ess  
There w as n o  
s ig nificant  
d if fere nce 
b etw een th e tw o 
gr ou p s  
W HO  
S ucralp hate 
Cas tagna L,  
B enh am ou  E,  
Ped raza E , 
Lu b oin ski  M ,  
Fo rn i  M , 
B ran des  I,  et 
al .( 27) 
D ou b le-
b lind  RC T,  
d iv id ed int o 
4 gr ou p s,  
accor d in g to  
th e 
co nd itio n ing 
reg im en,  
b ased  on  
th e 
p ro bab il i ty 
o f 
d evelop in g 
rad iat io n-
ind uced  
mu co sitis 
(R T) 
105  
SG =  5 3 
CG =  52 
M o u thw ash w ith 
o n e do se o f 
su lcr ap h ate (2g) v s 
p lacebo .  G uid ance:  
in ges t on e do se (2 g) 
o f sulcrap h ate ev ery 
t hr ee h o ur s,  up  to a 
m aximu m o f seven  
m o uth w ashes  in  24 
h o ur s  
M uco sitis 
in ciden ce and  
ser iousn ess , 
diahr rea  
M uco s itis  
incid ence  w as 
s im i lar  f or  bo th  
gr ou p s,  bu t the 
p rop or tion  of  
p atients  w ith  
w ith d egre es 3- 4 
m uco s itis  w as  
h ig her  fo r th e 
p laceb o  gro up   
O M AS 
Tr aum eel  
S ® 
Ob erb aum  M , 
Y an iv  I ,  B en -
G al Y ,  S tein J,  
B en- Zv i N , 
Fr eedm an  LS , 
B ran sk i D .( 28) 
D o ub le -
b lind  RC T  
3 0 
SG =  1 5 
CG =  15 
P laceb o (C G) v s 
T RAUM E E L S®  
( SG ), 5 times  a day,  
f or  at leas t 14 d ays 
M uco sitis 
ser iousn ess  
S ign ificant  
r edu ctio n  of  
m uco s itis  
s eriou sness and  
/ o r du ratio n 
w h en co mp ared  
w ith th e p laceb o 
gr ou p  (p< 0.01 ) 
N o t 
m en tio n ed 
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